Regulatory T cells, tumour immunity and immunotherapy - PubMed (original) (raw)
Review
doi: 10.1038/nri1806.
Affiliations
- PMID: 16557261
- DOI: 10.1038/nri1806
Review
Regulatory T cells, tumour immunity and immunotherapy
Weiping Zou. Nat Rev Immunol. 2006 Apr.
Abstract
Tumours express a range of antigens, including self-antigens. Regulatory T cells are crucial for maintaining T-cell tolerance to self-antigens. Regulatory T cells are thought to dampen T-cell immunity to tumour-associated antigens and to be the main obstacle tempering successful immunotherapy and active vaccination. In this Review, I consider the nature and characteristics of regulatory T cells in the tumour microenvironment and their potential multiple suppressive mechanisms. Strategies for therapeutic targeting of regulatory T cells and the effect of regulatory T cells on current immunotherapeutic and vaccine regimens are discussed.
Similar articles
- Regulatory T cells: potential target in anticancer immunotherapy.
Juang CM, Hung CF, Yeh JY, Horng HC, Twu NF, Cheng MH, Wen KC, Yuan CC, Chao KC, Wu TC, Yen MS. Juang CM, et al. Taiwan J Obstet Gynecol. 2007 Sep;46(3):215-21. doi: 10.1016/S1028-4559(08)60023-6. Taiwan J Obstet Gynecol. 2007. PMID: 17962099 Review. - CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
Wang RF. Wang RF. Hum Immunol. 2008 Nov;69(11):811-4. doi: 10.1016/j.humimm.2008.08.276. Epub 2008 Sep 24. Hum Immunol. 2008. PMID: 18817828 Review. - Reversal of tumor-mediated immunosuppression.
Vieweg J, Su Z, Dahm P, Kusmartsev S. Vieweg J, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):727s-732s. doi: 10.1158/1078-0432.CCR-06-1924. Clin Cancer Res. 2007. PMID: 17255301 Review. - TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H, Marshall NA, Mills KH. Conroy H, et al. Oncogene. 2008 Jan 7;27(2):168-80. doi: 10.1038/sj.onc.1210910. Oncogene. 2008. PMID: 18176598 Review. - Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y, Shah S, Qiao L. Huang Y, et al. Arch Immunol Ther Exp (Warsz). 2007 Jul-Aug;55(4):205-17. doi: 10.1007/s00005-007-0029-3. Epub 2007 Jul 23. Arch Immunol Ther Exp (Warsz). 2007. PMID: 17659376 Review.
Cited by
- ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma.
Gao WN, Chen LG, Bao LR, He N, Hu TL, Lai C, Xu RF, Wang XF, Wang JY, Zhao JR, Meng Y. Gao WN, et al. Sci Rep. 2024 Oct 1;14(1):22775. doi: 10.1038/s41598-024-73574-7. Sci Rep. 2024. PMID: 39353993 Free PMC article. - Is a 3 mm Surgical Margin Safe for Basal Cell Carcinoma in the Head and Neck that is Less than 2 cm, Considering Different Risk Factors?
Yong MJ, Yoo SJ, Shin HK. Yong MJ, et al. Arch Plast Surg. 2024 Aug 6;51(5):487-494. doi: 10.1055/a-2338-9192. eCollection 2024 Sep. Arch Plast Surg. 2024. PMID: 39345996 Free PMC article. - Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profiling.
Syrimi E, Khan N, Murray P, Willcox C, Haigh T, Willcox B, Masand N, Bowen C, Dimakou DB, Zuo J, Barone SM, Irish JM, Kearns P, Taylor GS. Syrimi E, et al. iScience. 2024 Aug 28;27(9):110837. doi: 10.1016/j.isci.2024.110837. eCollection 2024 Sep 20. iScience. 2024. PMID: 39310750 Free PMC article. - Barriers and opportunities in pancreatic cancer immunotherapy.
Ju Y, Xu D, Liao MM, Sun Y, Bao WD, Yao F, Ma L. Ju Y, et al. NPJ Precis Oncol. 2024 Sep 12;8(1):199. doi: 10.1038/s41698-024-00681-z. NPJ Precis Oncol. 2024. PMID: 39266715 Free PMC article. Review. - Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer.
Li P, Yang Y, Wang Y, Zheng J, Chen F, Jiang M, Chou CK, Cong W, Li Z, Chen X. Li P, et al. Research (Wash D C). 2024 Sep 6;7:0444. doi: 10.34133/research.0444. eCollection 2024. Research (Wash D C). 2024. PMID: 39247806 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources